New data released into our Nitrites in Excipients Database

Lhasa Limited releases new data to Nitrites in Excipients project users.

14 December 2021

Data release: Lhasa releases new data into its Elemental Impurities Database

08 December 2021

Nitrites in Excipients Data Sharing Initiative: New Data Release

07 October 2021

20 tips for nitrosamine impurity assessment

Many readers will be aware of the risk posed by nitrosamine impurities, as an ongoing pharmaceutical industry hot topic. In July 2021 ANVISA published their guidance for assessment and control of potentially carcinogenic nitrosamines in active pharmaceutical ingredients and drug products. To discuss this topic, we invited knowledgeable speakers from ANVISA, Industry - GSK and Libbs Farmacêutica - and Lhasa to give their perspectives on this topic. This article details the top 20 take away points from the workshop for quick and easy consumption - enjoy!

05 August 2021

The top 5 benefits of data sharing with Vitic [an infographic]

08 April 2021

Working together to address the potential presence of nitrosamine impurities in medications

25 January 2021

Lhasa Limited announces the release of Effiris 2.2 - providing accurate secondary pharmacology predictions for novel compounds

Effiris delivers state-of-the-art secondary pharmacology models, where each model is able to learn from the private data of all pharmaceutical collaborators. As a result, Effiris overcomes one of the main challenges facing model development in drug discovery - accessing and utilising high-quality proprietary data.

Prior to this release, Effiris already offered model building – the ability to build teacher models in Effiris using in-house confidential data, privacy-preserving data sharing – the production of label files which extract knowledge while preserving all confidential aspects of the compounds used, and hybrid model building – collating Effiris member’s confidential dataset labels with the shared knowledge available in Effiris and publicly available data, in order to generate more comprehensive dataset to build a hybrid models.

What can you expect from Effiris 2.2?...

17 January 2022

Reflecting on 2021 and planning 2022

Our CEO, Dr Chris Barber reflects on a successful 12 months for Lhasa and discusses our plans for the year ahead.

20 January 2022

Lhasa Limited announces the release of Effiris 2.2 - providing accurate secondary pharmacology predictions for novel compounds

Effiris delivers state-of-the-art secondary pharmacology models, where each model is able to learn from the private data of all pharmaceutical collaborators. As a result, Effiris overcomes one of the main challenges facing model development in drug discovery - accessing and utilising high-quality proprietary data.

Prior to this release, Effiris already offered model building – the ability to build teacher models in Effiris using in-house confidential data, privacy-preserving data sharing – the production of label files which extract knowledge while preserving all confidential aspects of the compounds used, and hybrid model building – collating Effiris member’s confidential dataset labels with the shared knowledge available in Effiris and publicly available data, in order to generate more comprehensive dataset to build a hybrid models.

What can you expect from Effiris 2.2?...

17 January 2022

New data released into our Nitrites in Excipients Database

14 December 2021

Data release: Lhasa releases new data into its Elemental Impurities Database

08 December 2021

Reflecting on 2021 and planning 2022

Our CEO, Dr Chris Barber reflects on a successful 12 months for Lhasa and discusses our plans for the year ahead.

20 January 2022

Predicting N-nitrosamine carcinogenic potency using structure-activity relationships (SARs)

17 December 2021

How Derek Nexus and Sarah Nexus meet the 5 OECD principles

30 November 2021